The new technologies of deep sequencing of DNA and RNA are clearing the way for unprecedented opportunities in genomic medicine. Medical scientists have used the supercomputer Norwegian Abel in Oslo to transform numbers and genomic sequences in a more personalized treatment for cancer and better level.
As the medicine enters the era of Big Data, it is essential to have high-performance computing and a powerful infrastructure. Medical science is one of the areas of science Big Data grows faster, generating tons of data from genome sequencing projects around the world. specialized in different areas scientists are joining forces, trying to analyze the huge and sometimes surprising amount of information. If they can achieve convert the information obtained from deep sequencing large cohorts of patients biomarkers, new drugs and a structure more personalized treatment, recent genomic advances will revolutionize cancer medicine.
No two cancers are alike
It is working hard to identify and catalog the entire population of the large number of possible genetic alterations that accumulate and can lead to cancer, and to separate natural variations mutations cause cancer risk.
The primary objective for this research is the personalized treatment of cancer. No two cancers are alike, and one of the weakest points of the regime of current treatments is that patients with cancer in the same organ typically receive the same line of medication, even if the cancers were caused by completely different molecular mechanisms . One of the major objectives of record and graph the many mutations that accumulate in cancer cells is a molecular improved stratification of different groups of patients. This will allow doctors to provide each patient a more precise compatible with their particular treatment of cancer mutation spectrum.
However, there is still a long way to go before it is clinically applied a genomic scale, Norwegian scientists are working on this momentous task in different ways. A collection is one of the largest sets of deep sequencing data samples from patients with colorectal and prostate cancer data. Researchers analyzed this material to find variants of RNA molecules, which are produced only by cancer cells, and thus could be used in improved methods for detecting cancer or cancer specific targets for therapies methods.
There are legal, social and ethical issues that must be confronted
While these high-performance technologies for genotyping are very promising, present challenges in other areas. There are legal, social and ethical issues that must be confronted. It must be implemented carefully privacy legislation to adequately manage the large volume of confidential patient information currently available.
And as genomics start integrated into medical treatments, current procedures will face ethical conflicts as if incidental findings should be delivered to the patient. There are several hidden secrets in DNA sequences, secrets that not everyone would know much less share.
But for the moment, while the science of Big Data is about to change the genomic landscape, opportunities to implement routine cancer treatments are unimaginable.
This is an abridged version of the original article written by Bjarne Johannessen and Rolf I. Skotheim in Meta Magazine, published by UNINETT Sigma 2:
For more information please contact our contributor(s):